Package Leaflet: Information for the User
Renagel 800 mg Film-Coated Tablets
Sevelamer Hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Package Leaflet:
Renagel contains the active substance sevelamer. This active substance binds to phosphate in the digestive tract and reduces phosphate levels in the blood.
Renagel is used to control high blood phosphate levels in adult patients with chronic kidney disease who are on dialysis (haemodialysis or peritoneal dialysis).
Adult patients with kidney disease who are on dialysis cannot control their serum phosphate levels. As a result, phosphate levels increase (your doctor will call this hyperphosphataemia). High phosphate levels can cause hard deposits in the body called calcifications. These deposits can harden blood vessels and make it more difficult for blood to be pumped through the body. High phosphate levels can also cause skin itching, red eyes, bone pain, and fractures.
Renagel can be used with other medicines, including calcium or vitamin D supplements, to control the development of bone disease.
Do not take Renagel:
Warnings and precautions
Tell your doctor before taking Renagel if you are in any of the following situations:
Tell your doctor while you are taking Renagel:
Additional treatments:
Because you have kidney disease or are on dialysis, you may experience:
Change of treatment:
When switching from another phosphate binder to Renagel, your doctor may need to monitor your bicarbonate levels more closely since Renagel can decrease bicarbonate levels.
Special note for patients on peritoneal dialysis
You may develop peritonitis (infection of the abdominal fluid) associated with peritoneal dialysis. This risk can be reduced with careful use of sterile techniques when changing bags. You should inform your doctor immediately if you have any new signs or symptoms of abdominal discomfort, abdominal swelling, abdominal pain, abdominal tenderness, or abdominal stiffness, constipation, fever, chills, nausea, or vomiting. Additionally, you may undergo more thorough checks to detect problems with low levels of vitamins A, D, E, K, and folic acid.
Children and adolescents
The safety and efficacy of Renagel in children (under 18 years) have not been established. Therefore, Renagel is not recommended for use in this population.
Using Renagel with other medicines
Tell your doctor if you are taking, have recently taken, or might take any other medicines.
Your doctor will check for possible interactions between Renagel and other medicines.
In some cases, Renagel must be taken at the same time as another medicine. Your doctor may tell you to take this medicine 1 hour before or 3 hours after taking Renagel, or may consider monitoring the blood levels of that medicine.
Pregnancy, breastfeeding, and fertility
The safety of Renagel in pregnant or breastfeeding women has not been established. Renagel should not be used in pregnant or breastfeeding women unless clearly necessary.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
Driving and using machines
Renagel is unlikely to affect your ability to drive or use machines.
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor. Your doctor will tell you the dose to take based on your serum phosphate levels. The recommended starting dose of Renagel for adults and the elderly (> 65 years) is 1 to 2 tablets 3 times a day with each meal.
Initially, your doctor will check your phosphate levels every 2-3 weeks and may adjust the dose of Renagel as needed (between 1 and 5 tablets of 800 mg per meal) to achieve an adequate phosphate level.
The tablets should be swallowed whole. Do not crush, chew, or break them before taking.
Patients taking Renagel should follow the diet and fluid intake prescribed by their doctor.
If you take more Renagel than you should
In case of possible overdose, contact your doctor immediately.
If you forget to take Renagel
If you miss a dose, it should be skipped, so you should take the next dose when it is due and with a meal. Do not take a double dose to make up for forgotten doses.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Since constipation, very rarely, could be an early symptom of bowel obstruction, it is important to inform your doctor or pharmacist of this symptom before or during treatment with Renagel.
The following side effects have been reported in patients taking Renagel:
Very common (may affect more than 1 in 10 people):
nausea, vomiting.
Common (may affect up to 1 in 10 people):
diarrhoea, indigestion, abdominal pain, constipation, flatulence.
Uncommon (may affect up to 1 in 100 people):
increased blood acidity.
Rare (may affect up to 1 in 10,000 people):
hypersensitivity.
Frequency not known (cannot be estimated from the available data):
cases of itching, rash, abdominal pain, slow intestinal movement, inflammation of small pouches in the intestine (diverticulitis), bowel obstruction (symptoms include severe swelling, abdominal pain, bloating, or cramps, severe constipation), rupture of the intestinal wall (symptoms include severe stomach pain, chills, fever, nausea, vomiting, or abdominal tenderness), severe inflammation of the large intestine (symptoms include severe abdominal pain, digestive disorders, or blood in the stool), and crystal deposits in the intestine.
Reporting of side effects:
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and/or bottle after “EXP”. The expiry date is the last day of the month stated.
Do not store this medicine at temperatures above 25°C. Keep the bottle tightly closed to protect it from moisture.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Composition of Renagel
Appearance and packaging of the product
Renagel tablets are film-coated, white, oval, and have RG800 engraved on one side.
The tablets are packaged in high-density polyethylene bottles with a child-resistant polypropylene cap and an induction seal.
The pack sizes are:
1 bottle of 100 tablets
1 bottle of 180 tablets
Multiple pack containing 180 tablets (6 bottles of 30 tablets)
Multiple pack containing 360 tablets (2 bottles of 180 tablets)
Multiple pack containing 540 tablets (3 bottles of 180 tablets)
Not all pack sizes may be marketed.
Marketing authorisation holder and manufacturer
Marketing authorisation holder:
Sanofi Winthrop Industrie
82 Avenue Raspail
94250 Gentilly
France
Manufacturer:
Genzyme Ireland Limited
IDA Industrial Park
Old Kilmeaden Road
Waterford
Ireland
Sanofi Winthrop Industrie
1 rue de la Vierge
Ambares et Lagrave
33565 Carbon Blanc cedex
France
You can obtain further information on this medicine by contacting the local representative of the marketing authorisation holder:
Belgium/Belgique/Belgien/Luxembourg/Luxemburg Sanofi Belgium Tel: + 32 2 710 54 00 | Lithuania Swixx Biopharma UAB Tel: +370 5 236 91 40 |
Hungary SANOFI-AVENTIS Zrt Tel: +36 1 505 0050 | |
Czech Republic Sanofi s.r.o. Tel: +420 233 086 111 | Malta Sanofi S.r.l. Tel: +39 02 39394275 |
Denmark Sanofi A/S Tel: +45 45 16 70 00 | Netherlands Sanofi B.V. Tel: +31 20 245 4000 |
Germany Sanofi-Aventis Deutschland GmbH Tel: 0800 52 52 010 Tel. from abroad: +49 69 305 21 131 | Norway sanofi-aventis Norge AS Tel: + 47 67 10 71 00 |
Estonia Swixx Biopharma OÜ Tel: +372 640 10 30 | Austria sanofi-aventis GmbH Tel: + 43 1 80 185 - 0 |
Greece sanofi-aventis Μονοπρ?σωπη AEBE Tel: +30 210 900 1600 | Poland Sanofi Sp. z o.o. Tel.: +48 22 280 00 00 |
Spain sanofi-aventis, S.A. Tel: +34 93 485 94 00 | Portugal Sanofi – Produtos Farmacêuticos, Lda. Tel: +351 21 35 89 400 |
France Sanofi Winthrop Industrie Tel: 0 800 222 555 Call from abroad: +33 1 57 63 23 23 | Romania Sanofi Romania SRL Tel: +40 (0) 21 317 31 36 |
Croatia Swixx Biopharma d.o.o. Tel: +385 1 2078 500 | Slovenia Swixx Biopharma d.o.o. Tel: +386 1 235 51 00 |
Ireland sanofi-aventis Ireland Ltd T/A SANOFI Tel: +353 (0) 1 4035 600 | Slovakia Swixx Biopharma s.r.o. Tel: +421 2 208 33 600 |
Iceland Vistor hf. Tel: +354 535 7000 | Finland Sanofi Oy Tel: + 358 201 200 300 |
Sanofi S.r.l. Tel: 800.536 389 Italy Sanofi S.r.l. Tel: 800 536 389 | Sweden Sanofi AB Tel: +46 (0)8 634 50 00 |
Cyprus C.A. Papaellinas Ltd. Tel: +357 22 741741 Latvia Swixx Biopharma SIA Tel: +371 6 616 47 50 | United Kingdom (Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2525 |
Date of last revision of this leaflet
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu